Cellphire, Inc., the global leader in long-term stabilization and storage of platelets, announced today that Keith A. Moskowitz, Ph.D. MPM, has joined the company as Vice President of Discovery. Dr. Moskowitz has more than two decades of leadership experience directing R&D, liaison and strategy in companies with revenues in excess of $1 billion.
Dr. Moskowitz has spent 20 years in technical, management and liaison positions in the areas of hemostasis and thrombosis, infectious and genetic diseases in a variety of medical industries, including laboratory and POC diagnostics, medical devices, biologicals and custom laboratory services. He has a thorough understanding of both domestic and international regulatory and distribution channels, OEM, government grants and contracts, cGMP and GLP and has taken several products from idea to market. He is the author of over four dozen peer reviewed publications, abstracts and patents and is a member of the American Society of Hematology, The American Society of Clinical Chemistry, The International Society for Hemostasis and Thrombosis and the American Academy of Project Management, The American Association for Clinical Chemistry and the American Association of Clinical Pathologists.
“We at Cellphire are thrilled to have Keith Moskowitz join our R&D team,” said Cellphire CEO Stephen Willard. “Keith brings a deep understanding and expertise in hemostasis, and we look forward to working with him to push our platform cell stabilization technology into new and exciting areas.”
Among his significant previous positions, Dr. Moskowitz served as Vice President of Technology and Development at PTS Diagnostics, Vice President of Product Development & Medical Science Liaison at TraumaCure, VP of Product Development at BioMarker Strategies and Director of Corporate Product Development at SeraCare Life Sciences, where he was also Director of manufacturing for its MD facilities and for custom laboratory services. He was Director of Hematology and R&D at Adlyfe, and Accumetrics where he was directly responsible for the development of the VerifyNow Rapid Platelet Function Assay.
Dr. Moskowitz holds a Bachelor of Science degree from Rutgers University, a Ph.D. – Biochemistry (PhD) degree from Temple University School of Medicine, was a post-doctoral fellow at the Mount Sinai Medical Center and is recognized as a Master Project Manager (MPM) by the American Academy of Project Management.
About Cellphire
Cellphire, Inc. is a biotechnology company developing next-generation therapeutics. The company is applying its proprietary cell stabilization technology to all cell types, including platelets, to develop lifesaving products. Its lead product is Thrombosomes®, a freeze-dried hemostatic derived from human platelets. Cellphire’s technology has potential applications across a wide range of medical applications from trauma to wound care, imaging, targeted drug delivery, and regenerative medicine. For more information, visit www.cellphire.com.
Contacts:
Media
Sharon Burns
Director, Communications
sburns@cellphire.com
Investor Relations
Tom Dann
Chief Investment Officer
tdann@cellphire.com